Mark J. Foley, CEO at Revance Therapeutics, Inc. (RVNC), sold 62,558 shares at $30.72 ($1.9M) on 2023-06-09, disclosed to the SEC on 2023-06-13.
Scheduled sale ($1.9M) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.72 | 31,279 | $961K | 50.0% |
| 2 | $30.72 | 31,279 | $961K | 50.0% |
| Total | $30.72 avg | 62,558 | $1.9M | 100% |
| Filing → |
| GKOS | SELL | 2024-02-26 | $847K | — | Filing → |
| RVNC | SELL | 2023-08-04 | $1.2M | — | Filing → |
| RVNC | SELL | 2023-07-05 | $1.3M | — | Filing → |